No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LLY240524C677500
- 133.00
- 0.000.00%
15min DelayTrading May 21 09:59 ET
0.00High0.00Low
0.00Open133.00Pre Close0 Volume0 Open Interest677.50Strike Price0.00Turnover1139.92%IV-2.37%PremiumMay 24, 2024Expiry Date152.72Intrinsic Value100Multiplier-9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9960Delta0.0002Gamma6.24Leverage Ratio-21.9878Theta0.0002Rho6.22Eff Leverage0.0006Vega
Intraday
- 5D
- 1D
News
Eli Lilly Granted Exclusive License to QurAlis Candidate for Neurodegenerative Diseases
Eli Lilly and Co's Options: A Look at What the Big Money Is Thinking
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and Co.Looking at options history for Eli Lilly and Co (NYSE:LLY) we detected 22 trades.If we consider the speci
While Dow Inc. futures are slightly down, IT and high tech stocks are being bought. Gamestop is rapidly rising in after-hours trading = US Stocks.
While Dow futures are slightly down in the US stock index futures market, buying is expanding in IT and high-tech stocks, causing the S&P 500 and NASDAQ 100 to rise today.
Structure Therapeutics' Stock Jumps on Weight-loss-pill Trial Results
By Eleanor Laise GLP-1 drugs in pill form could improve the medications' accessibility and affordability, analysts say Structure Therapeutics Inc.'s American depositary receipts (GPCR) gained more t
Express News | Quralis: Eligible for Future Milestone Payments of up to $577 Mln & Tiered Royalties on Net Sales
Express News | Quralis: Grants Eli Lilly Exclusive License for Qrl-204, Potential Precision Therapy for Restoration of Unc13a Function in ALS & Ftd
Comments
$Viking Therapeutics(VKTX.US$ yes company very cheap considering how much total market valuations the other three companies have achieved from just GLP-1 market (Obesity) contribution alone
$Eli Lilly and Co(LLY.US$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US$ 50-100 Billion if not wrong
$Amgen(AMGN.US$ 20+ Billion on no data yet
$Eli Lilly and Co(LLY.US$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US$ 50-100 Billion if not wrong
$Amgen(AMGN.US$ 20+ Billion on no data yet
1
1
In the last 18 months, $Eli Lilly and Co(LLY.US$ 's mkt cap has moved from $340B to roughly $770B today, there has to be close to $300-$400B attributed to GLP-1, agree? If close to being true, this just simply points to dramatic undervaluation of $Viking Therapeutics(VKTX.US$ with only a $7B mkt cap and what looks like a better GLP-1 franchise. Big pharma wastes a lot of money on stupid deals but this one at $15B is a lay-up. I think a BO happens any day and at a huge premium. Anyone smart enough to buy...
3
Nvidia delighted investors when it announced a 10-for-1 stock split last week. The move may be the start of a trend, as several prominent tech companies trade at prices high enough to tip the scales toward similar splits, according to a note from Bank of America.
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
72
2
$Hims & Hers Health(HIMS.US$ has added GLP-1 weight-loss injections to its portfolio of products.
The injections will have the same active ingredient as $Novo-Nordisk A/S(NVO.US$ ’s Ozempic and Wegovy.
HIMS stock is up by nearly 100% year-to-date.
Hims & Hers added that it would provide branded GLP-1 injections once supply catches up with demand. In the upcoming months, Hims & Hers will work towards providing access to compounded tirzepatide, whic...
The injections will have the same active ingredient as $Novo-Nordisk A/S(NVO.US$ ’s Ozempic and Wegovy.
HIMS stock is up by nearly 100% year-to-date.
Hims & Hers added that it would provide branded GLP-1 injections once supply catches up with demand. In the upcoming months, Hims & Hers will work towards providing access to compounded tirzepatide, whic...
4
Read more
communicative Axolot : that's cute did you know you can get all the glp1 drugs on Facebook for about 50$ a vial with out a script from hundreds of research grade suppliers?